United Therapeutics' Unituxin Disappoints In SCLC
Impact Likely Minimal On Company's Growth
Executive Summary
Targeting gangliosides expressed on SCLC tumors has been explored by United Therapeutics in the Phase II/III DISTINCT study, but top-line results show no effect on overall survival.